Differential immunotropic therapy of patients with acne

Acne (Acne vulgaris) is one of the most common skin diseases (registered in 80-90% of teenagers and young people of working age) with the localization of acne on exposed skin, has a chronic course that causes psycho-emotional changes in patients and reduces their quality of life.Objective. To improve the treatment of patients with acne depending onthe clinical manifestations of dermatosis and the state of their systemicimmunity through the differentiated use of immunotropic drugs.Material and methods. A comprehensive immunological examinationand treatment of 146 patients with acne aged 19 to 25 years, of which 77(52.7%) were female and 69 (47.3%) were male. The control groupconsisted of 35 healthy individuals (donors) of similar age and sex.Results. All 146 examined patients with acne were diagnosed with aninflammatory form of acne, including: in 37 (25.3%) patients - mildclinical course, in 83 (56.8%) - moderate severity and in 26 (17.9%) -severe clinical course of acne. The immunological study revealedsignificant changes in immune parameters in patients with severe andmoderate clinical course of acne, while a slight change in the immunitywas found in the patients with mild stage of acne. According to thesechanges in the immunological parameters of patients with acne, animmunotropic drug glucosaminylmuramyl dipeptide (lycopid) wasprescribed differently - 2 mg twice a day for 10 days (for the patients with moderate acne) and 10 mg once a day for 10 days (for the patients with severe clinical picture). This kind of treatment led to a positive dynamics of immunological parameters of the blood in such patients.Conclusion. Differentiated immunotropic therapy as a component ofcomplex treatment of patients with acne with the prescribtion of theimmunotropic drug glucosaminylmuramyl dipeptide (lycopid) allows usto improve the results of treatment, which is confirmed by the significantpositive dynamics of clinical and laboratory parameters.